Abstract

1. Abstract
1.1. Background: Recently the guidelines of European Association of Preventive Cardiology reported that the prevalence of diabetes mellitus in patients with diastolic heart failure (HFpEF) is around 31%. The ADA recommends using any of these four criteria for diabetes diagnosis Haemoglobin A1C ≥6.5% or Fasting plasma glucose (FPG) ≥126 mg/dL or random plasma glucose (PG) ≥200 mg/dL.Glunovo® is a transdermal device capable of detecting and storing the concentration of glucose in the abdominal interstitial fluid 480 times a day for up to 14 consecutive days. It is a new generation system for the continuous monitoring of blood glucose. It also allows the display of graphs regarding the trend and distribution of glycaemic results, that provides a Glucose Data Curve: the graph consists of measurement data every 3 minutes stored for up to 14 days. In this study we used this monitoring system in patients with diastolic heart failure.